Two months after a paper in PLoS One highlighted the potential of Koronis Pharmaceuticals Inc.'s HIV candidate KP-1461, the Seattle-based firm is working on the design of a Phase II study aimed at establishing dose and treatment duration for the drug. Read More
Cyrenaic Pharmaceuticals Inc. is a little company with big dreams. The privately held biotech, based in Princeton, N.J., is focused on the development of CYR-101, an antipsychotic in clinical development for the treatment of schizophrenia. Read More
Researchers, regulatory agencies and the general public have become much more interested in funding transparency in recent years – for obvious reasons. Studies that are funded by a drug maker are, on the average, more sanguine about a given drug than those that are not. Read More
Exelixis Inc., of South San Francisco, completed its public offering of 17.25 million shares, including 2.25 million shares in the fully exercised overallotment option. Read More
Apeiron Biologics AG, of Vienna, Austria, and the Cleveland Clinic Foundation, of Cleveland, have agreed to collaborate on anticancer compounds currently in development at the clinic. The collaboration includes an option to Apeiron to enter a worldwide, exclusive license agreement with the clinic relating to the compounds, and an Apeiron-sponsored research agreement with the clinic relating to those compounds and approach, the company said. Read More
Oxford BioMedica plc, of Oxford, UK, reported further analyses from its Phase III trial of cancer vaccine TroVax showed that, when applying the immune response surrogate (IRS) algorithm for predicting quantitative 5T4 antibody response, a significant correlation was seen between the antibody response induced following TroVax vaccination and treatment benefit. Patients with higher IRS values treated with TroVax survived longer than patients in the placebo group with the same IRS values. IRS also was associated with 5T4 antibody response and survival when applied to an independent dataset derived from the nine previous Phase I and Phase II studies of TroVax in patients with renal, colorectal and prostate cancer. Read More
